Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Selective Orexin-1 Receptor Antagonist Attenuates Stress-Induced Hyperarousal without Hypnotic Effects
Pascal Bonaventure, Sujin Yun, Philip L. Johnson, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 352, Iss. 3, pp. 590-601
Open Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

Sleep disturbance in PTSD and other anxiety-related disorders: an updated review of clinical features, physiological characteristics, and psychological and neurobiological mechanisms
Anne Richards, Jennifer C. Kanady, Thomas C. Neylan
Neuropsychopharmacology (2019) Vol. 45, Iss. 1, pp. 55-73
Open Access | Times Cited: 153
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia
Paul J. Coleman, Anthony L. Gotter, W. Joseph Herring, et al.
The Annual Review of Pharmacology and Toxicology (2016) Vol. 57, Iss. 1, pp. 509-533
Closed Access | Times Cited: 113
Orexins and stress
Laura A. Grafe, Seema Bhatnagar
Frontiers in Neuroendocrinology (2018) Vol. 51, pp. 132-145
Open Access | Times Cited: 106
Orexins and fear: implications for the treatment of anxiety disorders
África Flores, Rocío Saravia, Rafaël Maldonado, et al.
Trends in Neurosciences (2015) Vol. 38, Iss. 9, pp. 550-559
Open Access | Times Cited: 92
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han, Kai Yuan, Yongbo Zheng, et al.
Neuroscience Bulletin (2019) Vol. 36, Iss. 4, pp. 432-448
Open Access | Times Cited: 77
Current models of insomnia disorder: a theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment
Laura Palagini, Pierre A. Geoffroy, Matteo Balestrieri, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 4
Closed Access | Times Cited: 25
Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist
Angela Glen, Roland W. Bürli, David G. Livermore, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 100, pp. 129629-129629
Open Access | Times Cited: 8
Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist
Yu Yoshida, Yoshimitsu Naoe, Taro Terauchi, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 11, pp. 4648-4664
Closed Access | Times Cited: 76
Recent trends in orexin research—2010 to 2015
Christoph Boss, Catherine Roch
Bioorganic & Medicinal Chemistry Letters (2015) Vol. 25, Iss. 15, pp. 2875-2887
Closed Access | Times Cited: 74
The roles of orexins in sleep/wake regulation
Michihiro Mieda
Neuroscience Research (2017) Vol. 118, pp. 56-65
Open Access | Times Cited: 73
The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468
Alexander Treiber, Ruben de Kanter, Catherine Roch, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 362, Iss. 3, pp. 489-503
Open Access | Times Cited: 69
The highly selective orexin/hypocretin 1 receptor antagonist GSK1059865 potently reduces ethanol drinking in ethanol dependent mice
Marcelo F. Lopez, David E. Moorman, Gary Aston‐Jones, et al.
Brain Research (2016) Vol. 1636, pp. 74-80
Open Access | Times Cited: 66
Sexually Dimorphic Changes of Hypocretin (Orexin) in Depression
Jing Lü, Juan Zhao, Rawien Balesar, et al.
EBioMedicine (2017) Vol. 18, pp. 311-319
Open Access | Times Cited: 65
Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine
Taylor A. Gentile, Steven J. Simmons, Mia N. Watson, et al.
Neuropsychopharmacology (2017) Vol. 43, Iss. 5, pp. 1001-1009
Open Access | Times Cited: 64
Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases
Alain Couvineau, Thierry Voisin, Pascal Nicole, et al.
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 63
Cyclic tailor-made amino acids in the design of modern pharmaceuticals
Jiang Liu, Jianlin Han, Kunisuke Izawa, et al.
European Journal of Medicinal Chemistry (2020) Vol. 208, pp. 112736-112736
Closed Access | Times Cited: 57
Recent perspectives on orexin/hypocretin promotion of addiction-related behaviors
F. Woodward Hopf
Neuropharmacology (2020) Vol. 168, pp. 108013-108013
Open Access | Times Cited: 50
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO2-INDUCED PANIC-ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES
Philip L. Johnson, Lauren M. Federici, Stephanie D. Fitz, et al.
Depression and Anxiety (2015) Vol. 32, Iss. 9, pp. 671-683
Open Access | Times Cited: 62
Recent advances in understanding the roles of hypocretin/orexin in arousal, affect, and motivation
Natalie Nevárez, Luı́s de Lecea
F1000Research (2018) Vol. 7, pp. 1421-1421
Open Access | Times Cited: 56
Therapeutics development for addiction: Orexin-1 receptor antagonists
David A. Perrey, Yanan Zhang
Brain Research (2018) Vol. 1731, pp. 145922-145922
Open Access | Times Cited: 55
Orexin 2 receptor regulation of the hypothalamic–pituitary–adrenal (HPA) response to acute and repeated stress
Laura A. Grafe, Darrell Eacret, Sandra Luz, et al.
Neuroscience (2017) Vol. 348, pp. 313-323
Open Access | Times Cited: 50
Sex differences in stress-related disorders: Major depressive disorder, bipolar disorder, and posttraumatic stress disorder
Dick F. Swaab, Ai‐Min Bao
Handbook of clinical neurology (2020), pp. 335-358
Closed Access | Times Cited: 47
Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans
Giacomo Salvadore, Pascal Bonaventure, Anantha Shekhar, et al.
Translational Psychiatry (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 40
Page 1 - Next Page

Scroll to top